

Index

- N*-acetyl aspartate
 - in ADHD 394
 - in obsessive–compulsive disorder 397–398, 399
 - in schizophrenia 380
 - predictive value 444
- ADHD *see* attention-deficit hyperactivity disorder
- adolescence 70, 445–446, 447, 458
 - at-risk population studies 445–446, 447
 - brain development 70–75
 - myelination 71, 332
 - synapse elimination 70–71, 458, 462
 - cognitive development 69, 72–75, 82–83
 - executive functions 73–74
 - etiological factors 462–463
 - sequelae of preterm birth 94–96
- affective disorders 390, 391
 - see also* bipolar disorder; depression
- African-Caribbeans in the UK 234–235
 - unemployment 236
- age of onset 274
 - possible origins of delayed onset 279–281
 - sex differences 331
- alpha-linolenic acid 160
 - see also* essential polyunsaturated fatty acids
- D-amino acid oxidase (DAO) gene 24
- amisulpiride 465
- amphetamine psychosis 250–251
 - genetic determinants 254
 - sensitization 260–261, 273
- amygdala 404–405
 - in bipolar disorder 112, 402, 404–405
 - in major depressive disorder 401–402
 - role in limbic lobe changes 298–299
 - fiber ingrowth into anterior cingulate cortex 302, 303–304
 - “mis-wired” circuit model 297, 304–305
 - sex differences 41
 - stress and emotional reactivity and 275, 276
- amygdala–hippocampal complex (AHC) volume
 - changes 359
 - in high-risk population 350–351
 - in unaffected relatives 358
 - see also* amygdala; hippocampus
- Angelman syndrome 184
- antecedents of schizophrenia *see* predictors of schizophrenia
- anterior cingulate 304
 - amygdalar fiber ingrowth 302, 303–304
 - dopamine input distribution 297–298
 - excitatory fiber changes 297, 298–299
 - in obsessive–compulsive disorder 396, 398, 404–405
- anticipation, genetic 339
- antidepressants 466
- antioxidants 158–159
 - dietary supplementation 163–164, 165, 467
 - when and what to treat 166
- antipsychotic drugs
 - adverse effects 159
 - anti/pro-oxidant properties 164
 - efficacy 159
 - secondary prevention strategies 465
- antisaccade task performance 53–55
- apoL lipoprotein 219–220
- apoptosis 162
 - neuropathological role 377–378, 382
 - synaptic 377–378
 - see also* synaptic pruning
- arachidonic acid (AA) 160
 - in schizophrenia 160, 162
 - role in membrane signal transduction 161–162
 - role in neurodevelopment 160–161
 - see also* essential polyunsaturated fatty acids
- arborization 39–40
- arcuate fasciculus 38

474 Index

- at-risk populations *see* high-risk population studies
- attention-deficit hyperactivity disorder (ADHD)
 - 40, 98, 390, 391–398
 - common neuropathology 391–398, 402–405
 - genetic basis 402–403
 - neuroimaging studies 57, 392–395
 - frontostriatal circuitry 393–395
 - total cerebral volume 392–393, 394
 - nutritional factors 166
 - role of basal ganglia 98
 - with velo-cardio-facial syndrome 124
- attentional processes
 - development 75
 - attentional set-shifting ability 74–75, 80–81
 - in schizophrenia 80–81
 - structural correlates 76–77
 - dysfunction as predictor of schizophrenia 423, 442–443
 - see also* cognitive development; cognitive dysfunction
- attenuated psychotic symptoms 445, 457
 - see also* prodromal phase
- automatic rerouting 100–101
- Barrington’s nucleus 276
- basal ganglia
 - in ADHD 98
 - in obsessive–compulsive disorder 399–400
 - in schizophrenia 141
 - sex differences 40–41
- BDNF *see* brain-derived neurotrophic factor
- behavior
 - conduct disorder 256–257
 - consequences of preterm birth 97
 - drug abuse and 255–257
 - in velo-cardio-facial syndrome 124–125
 - predictors of schizophrenia 425–426, 428, 437–438
 - archival–observational studies 428
 - high-risk studies 427
 - population-based studies 425–427
 - see also* obsessive–compulsive disorder
- bipolar disorder (BPD) 390, 391–398
 - common neuropathology 112–113, 390, 391, 403, 404–405
 - genetic basis 403
 - neuroimaging studies 400–402
 - frontal cortex 401
 - medial temporal cortex 401–402
 - total brain volume 400–401
 - postmortem findings 295–298
 - dopamine system 297–298
 - GABA system 296–297
- boxcar design 48–49
- brain
 - aging 332–333
 - sex differences 40–41, 331–333
 - structural abnormalities
 - as potential endophenotypes 139
 - epigenetic model and 187
 - in ADHD 392–395
 - in obsessive–compulsive disorder 395–400
 - in schizophrenia 141–142, 174, 347–348, 350, 415
 - in unaffected relatives 143–148
 - in velo-cardio-facial syndrome 129–131
 - molecular genetics 148–149
 - predictive value 443–444
 - progressive structural changes 142, 379, 381, 459
 - state versus trait 142–143
 - see also* premorbid structural abnormalities; *specific abnormalities*
 - structural heritability 139–141
 - structure and function relationship 97–98
 - remapping following brain injury 100
 - see also* plasticity
 - total brain size 35–36, 40
 - in bipolar disorder 400–401
 - in high-risk population 351–352
 - in major depressive disorder 400–401
 - in obsessive–compulsive disorder 396
 - in unaffected relatives 145
 - in velo-cardio-facial syndrome 129
 - progressive decline 379–380
 - see also* brain development; brain injury; central nervous system
- brain-derived neurotrophic factor (BDNF) 13, 15, 216, 258, 335
 - BDNF gene 17
 - brain morphometry and 149
 - changes in schizophrenia 16
 - expression 16
- brain development 5–6, 39, 330, 332–335
 - aberrations 77–82, 142–143
 - animal models 278–279
 - childhood injury 78
 - developmental lesions 78–79
 - epigenetic model and 180–181
 - etiological factors 462–463

475 Index

- impact of 77–79
- in schizophrenia 72, 79–82, 174–175, 278
- predictive value 443–444
- sequelae of preterm birth 94–96
 - see also* premorbid structural abnormalities
- brain function 45
 - electroencephalography studies 47
 - fMRI studies 47–55, 56–57
 - language development 56–57, 89–90
 - PET studies 47
- cell adhesion 10–14
- cognitive development relationships 75–77, 83
 - see also* cognitive development
- corpus callosum 38
- critical periods 90, 445–446
- dopaminergic system 334
- during adolescence 70–75
 - myelination 71, 332
 - synapse elimination 70–71, 458, 462
- estrogen role 334–335
- genetic basis 6–8
 - epigenetic factors 185
 - see also* transcriptomes
- gray matter 39–40
- MDN–DLPFC circuitry 311, 317–321
- nutrition role 158
 - essential polyunsaturated fatty acids 160–161
- schizophrenia as model 79–82
- segmentation 8–10
- serotonergic system 333–334
- sex differences 332–333
 - aging 332–333
 - estrogen role 334–335
 - myelination 332
- social factors 239
 - animal models 224–226
 - see also* limbic lobe; neurodevelopmental model; plasticity
- brain injury
 - childhood injury 78
 - following preterm birth 92
 - consequences of persisting abnormality 96–97
 - patterns of 93–94
 - prevalence 94
 - sequelae in adolescents 94–96
 - University College Hospital London Study 92–93
 - perinatal, drug abuse and 260
 - plasticity after 91–92, 99–101
 - at the connectivity level 100–101
 - at the neural network level 99–100
 - at the neuronal level 99
 - Kennard principle 91
 - limits of 101
 - remapping of functions 100
 - rerouting 100–101
 - see also* obstetric complications
- breast-feeding 162
- Brn-1 transcription factor 10
- Brn-2 transcription factor 10
- Broca, Paul 91
- Broca’s area 38
 - language function 56, 91
- cadherins 10–12
 - cadherin motif 10–11
 - cadherin neuronal-related receptors (CNRs) 11–12
 - seven-pass transmembrane cadherins 11
- Cajal–Retzius neurons 14
- Cambridge Neuropsychological Test Automated Battery (CANTAB) 73
- cannabis-induced psychosis 251–253, 257
 - sensitization 260–261
- CATCH 22 (cardiac anomalies, abnormal facies, thymic hypoplasia, cleft palate, and hypocalcemia) 123
 - see also* velo-cardio-facial syndrome
- catechol-O-methyltransferase 128
 - COMT gene 127, 128, 403
 - in bipolar disorder 403
 - methamphetamine abuse and 259
 - polymorphisms 128
- caudate nuclei
 - ADHD and 98, 395
 - in obsessive–compulsive disorder 399–400
- cell adhesion 10–14
- cell adhesion molecules (CAMs) 10–13
 - cadherin superfamily 10–12
 - immunoglobulin superfamily (IgSF) 10, 12–13
 - NCAM 12–13
- cell differentiation 180
 - embryonic cells 181, 182
- central nervous system (CNS) development 3
 - cell adhesion 10–14
 - genetic mechanisms 3, 6–8
 - neuronal survival 14–18
 - neurulation 5–8
 - segmentation 8–10
 - see also* brain development

476 Index

- cerebellar cognitive–affective syndrome 98
 - cerebellum
 - in ADHD 395
 - in velo-cardio-facial syndrome 129, 130
 - sequelae of preterm birth 95
 - consequences 98
 - cerebral atrophy, following preterm birth 94
 - cerebral blood flow (CBF), estrogen effect 336
 - cerebral cortex, asynchronous development 332
 - see also* brain development
 - cerebral volume 37
 - heritability 140
 - in ADHD 392–393, 394
 - in schizophrenia 141
 - in unaffected relatives 145–146
 - IQ relationship 36
 - sex differences 40
 - cerebrospinal fluid (CSF), sulcal spaces 145–146, 355
 - chandelier neurons 320–321
 - abnormalities in schizophrenia 323–324
 - childhood abuse 228–229, 239
 - childhood antecedents *see* predictors of schizophrenia
 - childhood behavior *see* behavior
 - childhood neuroimaging *see* pediatric neuroimaging
 - chromosome 22q11.2 deletion 126–127
 - see also* velo-cardio-facial syndrome
 - ciliary neurotrophic factor (CNTF) 18
 - cingulate 404–405
 - see also* anterior cingulate
 - city of birth effect 191, 230
 - city of upbringing effect 230
 - civilization 157
 - clinical high-risk studies 438–439
 - see also* high-risk population studies
 - cloning studies 184
 - clozapine 467
 - cocaine-induced psychosis 259
 - sensitization 260
 - cognition 72
 - estrogen effect 335–336, 337, 338
 - social cognition 339
 - see also* cognitive development; cognitive dysfunction
 - cognitive behavioral therapy (CBT) 465, 466
 - cognitive development 46–47, 69–70, 82, 311
 - cerebral development relationships 75–77, 83
 - during adolescence 69, 72–75, 82–83
 - executive functions 73–74
 - early brain lesion effects 79
 - pediatric fMRI studies 47–55
 - schizophrenia as model 79–82
 - voluntary response suppression 51–55
 - working memory 49–51, 73
 - in schizophrenia 80–81
 - structural correlates 76
 - see also* attentional processes; executive functions
 - cognitive dysfunction 310
 - glutamate role 460–461
 - in velo-cardio-facial syndrome 123–124
 - predictive value 419–425, 442–443, 458
 - high-risk studies 423–425
 - population-based studies 419–423
 - premorbid phase 376, 455–457
 - progressive impairment 375–376, 381
 - social factors 238
 - see also* working memory
- cohort studies 433–434
- communal upbringing 227–228
- communication deviance in parents 227
- complexins 22
- complexin I 22
- complexin II 22
- COMT *see* catechol-*O*-methyl transferase
- conduct disorder 256–257
- conotruncal anomaly face syndrome 123
 - see also* velo-cardio-facial syndrome
- coordination problems 417–418
- Copenhagen High-Risk Project 350, 354, 361, 363
- corpus callosum (CC) 36–38
 - development 38
 - function 38
 - in ADHD 395
 - in bipolar disorder 402
 - in depression 402
 - in obsessive–compulsive disorder 400
 - in unaffected relatives 147
 - sex differences 331–332
 - thinning following preterm birth 95
 - consequences 98
- cortical dysgenesis 129
- cortical volume reduction 111–112
 - animal model 279
- corticotropin-releasing factor (CRF) 113–114, 115
 - stress response 275–276

477 Index

- cortisol 116
 - in major depression 113, 116
 - in schizophrenia 115
- critical periods of development 90, 445–446
 - for learning 90
- cultural differences
 - ethnic minority status 233–234
 - methodological issues 234
 - nutrition 157
 - schizophrenia outcome 157–158
- DA *see* dopamine
- DAO gene 24
- deficit syndrome 375
- deletion 22q11.2 *see* chromosome 22q11.2
 - deletion
- Delta gene 6–7
- delta sleep 458
- dementia praecox 373
- depression
 - common neuropathology 112–113
 - cortisol role 116
 - glucocorticoid-related neurotoxicity 113
 - hypothalamic–pituitary–adrenal axis
 - abnormalities 113–114, 115–116
 - see also* major depression
- deprivation 237
- development
 - CNS 3
 - critical periods 90, 445–446
 - epigenetic factors 179–187
 - see also* brain development;
 - neurodevelopmental model
- developmental compensation *see* plasticity
- developmental delays
 - in velo-cardio-facial syndrome 123–124, 174
 - predictive value 418
- diencephalon 6
- diet *see* nutrition
- dietary supplementation *see* nutritional strategies
- diffusion tensor imaging (DTI) 36, 61–62
- DiGeorge syndrome 123
 - see also* velo-cardio-facial syndrome
- discrimination 235–236, 239
- dissociative identity disorder 229
- distributed neural systems 36
- dizygotic (DZ) twin studies *see* twin studies
- Dlx1 gene 9
- Dlx2 gene 9
- DNA demethylase 175
- DNA methylation 175–177
 - during embryogenesis 182–183
 - cloned embryos 184
 - knockout models 184
 - maintenance 180–181
 - see also* epigenetics
- DNA microarray studies 210–212
 - cDNA microarrays 211–212
 - future directions 220
 - synthetic oligonucleotide probe arrays 212
 - transcriptome assessment 210
 - data analysis and interpretation 214–215
 - experimental design 212–213
 - gene expression changes in schizophrenia 215–220
- DNA methyltransferases 175
- docosahexaenoic acid 160
 - dietary supplementation 163–165
 - in schizophrenia 160, 162
 - role in membrane signal transduction 161–162
 - role in neurodevelopment 160–161
 - see also* essential polyunsaturated fatty acids
- dopamine (DA) system 281–285
 - D₁ receptor 461–462
 - D₂ receptor (*DRD2*) gene 258
 - D₃ receptor (*DRD3*) gene 258
 - D₄ receptor (*DRD4*) gene 258–259
 - development 301, 304, 334
 - late maturation of dopamine projections 301–303
 - estrogen effect 336–337
 - in ADHD 395, 403
 - in schizophrenia 273, 281–285, 402–403
 - glutamatergic effects 460–462
 - sensitization 261, 273
 - phasic dopamine levels 283
 - postmortem findings 297–298
 - regulation 281–285, 460–462
 - sensitization 260–261
 - in schizophrenia 261, 273
 - stress response 277, 281
 - tonic dopamine levels 283
- dorsolateral prefrontal cortex (DLPFC) *see* MDN–DLPFC
 - circuitry; prefrontal cortex
- drug abuse
 - as cause of psychosis 250–254
 - amphetamine-induced psychosis 250–251
 - cannabis-induced psychosis 251–253

478 Index

- drug abuse (*cont.*)
 - individual differences in liability 254
 - LSD-induced psychosis 253–254
 - phencyclidine-induced psychosis 253
- association with psychosis 248–249
 - childhood development and personality factors 255–257
 - familial predisposition 257–258
- direction of association 249–250
 - common factor hypothesis 249–250
 - self-medication 249
 - vulnerability hypothesis 250
- dopamine sensitization 260–261
- molecular genetic studies 258–260
 - dopamine D₂ receptor gene 258
 - dopamine D₃ receptor gene 258
 - dopamine D₄ receptor gene 258–259
- perinatal brain damage, animal models 260
- dysbindin* gene 24
- dysfunctional family environment 227
- dyslexia, neuroimaging studies 57–58
- early parental loss 228
- early rearing environment 200
- economic deprivation 237
- Edinburgh High Risk Study (EHRS) 350–351
- EF motif *see* cadherin motif
- eicosapentaenoic acid (EPA) 160
 - dietary supplementation 163–165
 - see also* essential polyunsaturated fatty acids
- electroencephalography (EEG), developmental studies 47
- embryogenesis 182–183, 184–185
 - pluripotent cell differentiation 181, 182
- emotional reactivity 275–277
- Emx1* gene 9
- Emx2* gene 9
- endophenotypes 138–139
 - cerebral volume 145–146
 - frontal lobe 147
 - subcortical structures 146
 - temporal lobe 146
 - ventricular enlargement 144–145
- enhanced high-risk strategies 439–440, 446
- environmental risk factors *see* risk factors
- epigenesis 179
- epigenetic inheritance system 177
- epigenetic landscape 180, 181, 185, 186
- epigenetic metastability 177, 178, 179
- epigenetics 175–177, 180, 181
 - misregulation 185–187
 - relevance to schizophrenia 178–179, 185–187
 - role in development 179–187
 - see also* DNA methylation; histone modification
- ES2* gene 127
- essential fatty acids (EFAs) 158–159
- essential polyunsaturated fatty acids (EPUFAs)
 - 159, 160
 - dietary intake 162–163
 - dietary supplementation
 - benefits 163–164, 166
 - dose and quality of EPUFA 165
 - duration of treatment 165
 - placebo control 165
 - preferred combination 165
 - type of EPUFA 164–165
 - when and what to treat 166
 - in schizophrenia 160, 162
 - role in membrane signal transduction 161–162
 - role in neurodevelopment 160–161
 - oxidative breakdown 163–164
 - antioxidant benefits 163–164
- estrogen 334–337, 340–341
 - effect on cognitive function 335–336, 337, 338
 - effect on dopaminergic function 336–337
 - effect on serotonergic system 336
 - role in brain development 334–335
 - therapeutic use 340
- estrogen receptors 335
- ethnic minority status *see* minority groups
- ethyleicosopentaenoic acid 466
- N*-ethylmaleimide-sensitive factor (NSF) 216
- evoked response potentials 438, 443
- executive functions 72
 - development 46, 72–74
 - attentional set-shifting ability 74–75, 80–81
 - frontal lobe development and 75–76
 - implications for neural development 80–81
 - in adolescence 73–74
 - see also* cognitive development
 - see also* working memory
- expressed emotion 228
- family factors *see* social factors
- family history 353–360
 - CT studies 354–355
 - structural MRI studies 355–356
- famine *see* malnutrition

479 Index

- α -fetoprotein 334–335
- first-episode studies 432
- FMRI* gene 184, 339
- fold changes 214
- follow-back studies 434
- forebrain development 5–6
 - see also* brain development
- fragile X syndrome 184, 339–340
- frontal lobes
 - cognitive development and 72, 75–76
 - in bipolar disorder 401
 - in major depressive disorder 401
 - in schizophrenia 349
 - in unaffected relatives 147
 - in velo-cardio-facial syndrome 129–130
 - outcome of frontal lesions 78–79
 - see also* brain; brain development
- functional magnetic resonance imaging (fMRI) 47, 48
 - abnormal populations 57–59
 - ADHD 57, 394–395
 - dyslexia 57–58
 - pediatric schizophrenia 58–59
 - block design 48–49
 - cognitive development studies 47–55
 - voluntary response suppression 51–55, 77
 - working memory 49–51
 - event-related designs 49
 - language development studies 56–57
 - pediatric studies 49, 57–59, 63
 - challenges 59–61
 - see also* magnetic resonance imaging (MRI); pediatric neuroimaging
- G72* gene 24
- GABA membrane transporter (*GAT1*) 320
- GABA system
 - abnormalities in schizophrenia 298, 299, 323–324
 - “mis-wired” circuit model 297, 304–305
 - development 299–301, 304
 - gene expression changes 216
 - postmortem findings 296–297
- gamma-aminobutyric acid *see* GABA
- gametogenesis 182
- Gbx2 9
- gender differences *see* sex differences
- gene–environment interaction 237–238, 447
- general population cohort studies 433–434
- genetic anticipation 339
- genetic factors
 - ADHD 402–403
 - bipolar disorder 403
 - obsessive–compulsive disorder 403
 - velo-cardio-facial syndrome 126–129
 - see also* genetics of schizophrenia
- genetic high-risk populations 435–437
 - preventive intervention strategies 464
 - see also* high-risk population studies
- genetics of schizophrenia 138–139, 273–274, 447
 - brain structure 148–149
 - epigenetic theory 178–179, 185–187
 - family history 353–360
 - gene expression changes 215–220
 - see also* DNA microarray studies
 - heritability 138, 435
 - imaging specific gene effects 358–360
 - multifactorial susceptibility model 138
 - neurodevelopmental mechanisms 3, 4, 24
 - epigenetic factors 175, 179–185
 - susceptibility gene identification 138, 217–218
 - see also* epigenetics; X chromosome
- germinal matrix haemorrhage 93
- glial cell loss 112
- glial-cell-derived neurotrophic factor (GDNF) 17–18
- gliosis 377
- β -globin gene regulation 182
- glucocorticoids
 - corticotropin-releasing factor regulation 114
 - glucocorticoid receptor (GR) 114, 116
 - mineralocorticoid receptor (MR) 114
 - neurotoxicity 113, 116
 - stress response 280–281
 - see also* cortisol
- glutamate
 - cognitive role 460–461
 - developmental role 460
 - neurodegeneration and 461
 - transmission 273
 - gene expression changes 216
 - see also* glutamatergic system
- glutamate receptor 2 (AMPA2) 216, 219
- glutamatergic system 459–462
 - glutamatergic fiber changes 298–299
 - in obsessive–compulsive disorder 398, 399–400
 - therapeutic strategies 466, 467
 - see also* glutamate

480 Index

- glutamic acid decarboxylase (GAD) 296–297, 300, 323
 - microarray studies 216, 219
- glycine 466
- glycogen synthase kinase 3 β 8
- gray matter 39–40
 - developmental changes 39–40
 - during adolescence 71, 332
 - in major depressive disorder 401
 - in schizophrenia 130, 131, 349, 379
 - progressive loss 379, 381
 - in ultra-high-risk population 352
 - in velo-cardio-facial syndrome 131
- GSCL (goosecoid-like) gene 127
- haloperidol 298
- Hensen’s node 5
- heritability
 - of brain structure 139–141
 - of schizophrenia 138, 435
 - see also* genetics of schizophrenia
- high-risk population studies 350–353, 432–436, 437, 440, 446–448
 - adolescents 445–446, 447
 - behavioral predictors 427, 437–438
 - clinical high-risk strategies 438–439
 - Copenhagen High Risk Project 350
 - Edinburgh High Risk Study 350–351
 - enhanced high-risk strategies 439–440, 446
 - follow-back studies 434
 - general population cohort studies 433–434
 - genetic high-risk studies 435–437
 - Melbourne High Risk Study 351–353
 - methodological issues 440–441
 - generalizability to schizophrenia 441
 - reliability of parental diagnoses 440
 - specificity to schizophrenia 440–441
 - neurobehavioral high-risk strategies 437–438
 - neurointegrative predictors 418
 - neuropsychological predictors 423–425
 - retrospective studies 434
 - structural imaging 353
 - family history 353–360
 - working memory 58–59, 274–275
- hindbrain development 5–6
 - see also* brain development
- hippocampus
 - possible origins of delayed disease onset 279–281
 - sequelae of preterm birth 95
 - sex differences 41
 - stress effects on 279–281
 - volume abnormalities 111, 112, 277
 - genetic basis 148–149
 - in high-risk population 351–352
 - in major depressive disorder 401–402
 - in unaffected relatives 146
 - neurotrophin 3 gene relationship 360
 - obstetric complications and 358, 362
 - see also* amygdala–hippocampal complex
- histone modification 176–177, 181–182
 - valproic acid effects 184–185
 - see also* epigenetics
- homeobox (*Hox*) genes 9
 - Hoxb1* 9
- homeodomain 9
- hormone replacement therapy (HRT) *see* estrogen
- hydrocephalus 94
- hyperactivity 20, 98
- hypofrontality 380
- hypothalamic–pituitary–adrenal (HPA) axis
 - abnormalities in major depression 113–114, 115–116
 - abnormalities in schizophrenia 115–116
 - amygdala influence 275
- hypothalamus, corticotropin-releasing factor (CRF)
 - hypersecretion 113–114
- hypoxia *see* obstetric complications
- immunoglobulin superfamily (IgSF) 10, 11, 12–13
 - NCAM 12–13
- inequality 237
- infections, as risk factors
 - neonatal and childhood 194
 - prenatal 193–194, 362
 - influenza 192–194
- influenza, prenatal, as risk factor 192–194
- inheritance *see* genetics of schizophrenia;
heritability
- injury *see* brain injury
- integrative neurochemical model 459–462
- intellectual capacity as predictor 419–420
- intelligence quotient *see* IQ
- interleukin-1 β gene 149
- intervention strategies 463–467
 - after disease onset 467
 - premorbid phase 463–464
 - at-risk populations 464
 - universal interventions 463–464

481 Index

- prodromal phase 464–467
 - low-dose atypical antipsychotic drugs 465
 - naturalistic treatment studies 465–466
 - non-antipsychotic medications 466
 - psychotherapeutic treatments 466–467
- intraventricular haemorrhage, preterm birth and 93
- IQ
 - brain size relationship 35–36
 - decline during adolescence 82
 - following preterm birth 96–97
 - in velo-cardio-facial syndrome 123, 124
 - predictive value 419–420
- isolation of rearing 225
 - see also* social factors
- Kennard principle 91
 - exceptions to 91–92
- Krox20* gene 8–9
- labor complications *see* obstetric complications
- lamotrigine 467
- language development 56–57, 89–90
 - critical periods 89–90
 - developmental compensation following brain injury 100–101
 - remapping 100
 - rerouting 100–101
 - in velo-cardio-facial syndrome 123, 124
 - predictive value 421
- learning, critical periods 90
- learning disabilities
 - in velo-cardio-facial syndrome 124
 - psychiatric disorders and 125
 - see also* language development
- life events 236–237
- limbic lobe 295, 296
 - amygdala role in changes 298–299
 - “mis-wired” circuit model 304–305
 - postnatal maturation of circuitry 299–304
 - amygdalar fiber ingrowth into anterior cingulate cortex 303–304
 - GABA system 299–301
 - late maturation of dopamine projections 301–303
- linolenic acid 160
 - see also* essential polyunsaturated fatty acids
- lithium 466
- locus coeruleus
 - corticotropin-releasing hormone effects 276
 - stress response 275, 276
- LSD psychosis 229
- magnetic resonance imaging (MRI) 35, 48
 - region of interest (ROI) approach 349
 - risk factor studies
 - family history 355–356
 - velo-cardio-facial syndrome 129–131
 - voxel-based morphometry (VBM) 349
 - see also* functional magnetic resonance imaging
- magnetic resonance spectroscopy (MRS) 62
 - phosphorus-31 62, 380
- major depressive disorder (MDD) 391–398
 - common neuropathology 112–113
 - hypothalamic–pituitary–adrenal axis abnormalities 113–114, 115–116
 - neuroimaging studies 400–402
 - frontal cortex 401
 - medial temporal cortex 401–402
 - total brain volume 400–401
 - see also* depression
- malate dehydrogenase (MAD1) 217
- malnutrition 156, 158
 - prenatal, as risk factor 194–195
 - see also* nutrition
- Mash1* gene 6
- MDN–DLPFC (mediodorsal nucleus–dorsolateral prefrontal cortex) circuitry 310, 312
 - development 311, 317–321
 - dysfunction in schizophrenia 321–324
 - function 310–311
 - future directions 324–325
 - organization 313–317
 - see also* mediodorsal nucleus; prefrontal cortex; thalamus
- MECP2* mutations 184
- mediodorsal nucleus (MDN) 310
 - volume reduction in schizophrenia 321, 322
 - see also* MDN–DLPFC circuitry; thalamus
- Melbourne High Risk Study (MHRS) 351–353
- memantine 467
- membrane signal transduction 161–162
- memory, estrogen effects 335–336
 - see also* working memory
- mental retardation
 - in fragile X syndrome 339
 - in velo-cardio-facial syndrome 123, 124

482 Index

- mental retardation (*cont.*)
 - psychiatric disorders and 125
 - see also* IQ
- mesencephalon development 5–6
- meta-cognition 69
- metabolic changes 216–217, 380
- metencephalon 6
- methamphetamine psychosis 250–251
 - familial predisposition to schizophrenia and 257–258
 - genetic studies 259
 - premorbid characteristics 255–257
 - sensitization 261
- N-methyl-D-aspartate receptors *see* NMDA receptors
- methyl azoxymethanol acetate (MAM) 278–279
- methylphenidate 394–395
- microarray studies *see* DNA microarray studies
- midbrain development 5–6
 - see also* brain development
- migration 233–234
 - see also* minority groups
- mineralocorticoid receptor (MR) 114
- minor physical anomalies as risk factors 195–196, 443
- minority groups 233–234
 - African-Caribbeans in the UK 234–235
 - discrimination 235–236, 239
 - methodological issues 234
 - second generation 235
- monozygotic (MZ) twin studies *see* twin studies
- mood disorders *see* bipolar disorder; depression
- mother–child relationship 226
- motor coordination dysfunction 417–418
- multifactorial susceptibility model 138
- myelination 36, 47, 332
 - diffusion tensor imaging studies 61–62
 - during adolescence 71, 332
 - gene expression changes 219
 - rerouting plasticity and 101
 - sex differences 332
- NAA (N-acetylaspartate)
 - in ADHD 394
 - in obsessive–compulsive disorder 397–398, 399
 - in schizophrenia 380
 - predictive value 444
- NCAM *see* neuronal cell adhesion molecule
- NCAM1 gene 12, 13
- negative symptoms 445
 - progression 375, 457
- neonatal risk factors 200
- nerve growth factor (NGF) 15, 335
 - expression 16
- neural ectoderm 5
- neural plate 5
- neural tube 5
- neurobehavioral high-risk studies 437–438
 - see also* high-risk population studies
- NeuroD 7
- neurodegenerative disorders 374
- neurodegenerative models 373, 382–383, 459
 - clinical psychopathology and cognition 374–376
 - integrative neurochemical model 459–462
 - neuroimaging studies 379–381
 - correlation between imaging data and outcome 380–381
 - functional and spectroscopic studies 380
 - structural studies 379–380
 - postmortem findings 376–378
 - potential mechanisms of neurodegeneration 381–382, 463
 - versus neurodevelopmental model 81–82, 111–112
- neurodevelopmental model 3, 79–82, 111, 174–175, 373, 415
 - animal models 277–279
 - early developmental model 457–458
 - genetic mechanisms 3, 4, 24
 - epigenetic factors 175, 179–187
 - integrative neurochemical model 459–462
 - late developmental model 458–459
 - limitations of 373
 - pediatric fMRI studies 58–59
 - support for 121
 - unifying model 455
 - velo-cardio-facial syndrome as model for schizophrenia 122
 - versus atrophy/neurodegeneration 81–82, 111–112
 - see also* brain development
- neurogenins 7
 - Ngn1 7
 - Ngn2 7
- neuromeres 6
- neuromotor dysfunction 417–418, 443
- neuron 37
- neuronal cell adhesion molecule (NCAM) 12–13
 - gene NCAM1 12, 13

483 Index

- function 12–13
- isoforms 12
- role in schizophrenia 13
- neuronal cell loss 377
- neuronal survival 14–18
- neuroregulin 1* gene 24
- neurotransmission 18–23
- neurotrophins (NT) 14–17, 335
 - NT-3 15, 335
 - A3 allele 360
 - expression 18
 - NT-4/5 15, 335
 - expression 16
 - NT-6 15
- neurulation 5–8
 - genetic basis 6–8
 - primary 5
 - secondary 5
- NMDA receptors 282, 460, 461–462
 - estrogen effect 335
 - phencyclidine effect 253
 - role in neurodegeneration 381–382
 - role in neurodevelopment 460
- Notch* genes 6–7
 - NOTCH4* 7–8
- NSF (*N*-ethylmaleimide-sensitive factor) 216
- NT-3* gene 17
 - see also* neurotrophins
- nutrition 156
 - role in brain and behavioral development 158
 - role in health 156
 - role in schizophrenia 156–157, 158–159
 - undernutrition 156, 158
 - prenatal malnutrition as risk factor 194–195
 - see also* essential polyunsaturated fatty acids
- nutritional strategies
 - dietary supplementation 159, 163–164
 - antioxidants 163–164
 - essential polyunsaturated fatty acids 163–165
 - preferred combination 165
 - issues 164–165
 - adjunctive medication 164
 - age and duration of illness 164
 - dose and quality of essential polyunsaturated fatty acids 165
 - duration of treatment 165
 - placebo control 165
 - type of essential polyunsaturated fatty acids 164–165
 - when and what to treat 166
- obsessive–compulsive disorder (OCD) 40–41, 390, 391–398
 - common neuropathology 391, 404–405
 - genetic basis 403
 - neurodevelopment 397, 398
 - neuroimaging studies 395–400
 - basal ganglia 399–400
 - prefrontal cortex 396
 - thalamus 399
 - total brain volume 396
 - with velo–cardio–facial syndrome 125
- obstetric complications (OCs) 143, 175, 197–199, 200–202, 403
 - imaging abnormalities and 360–363
 - hippocampi 358, 362
 - ventricles 360–361
 - neurodevelopmental deficits and 419
- OCD *see* obsessive–compulsive disorder
- oculomotor delayed response (ODR) task 58–59, 310–311
 - see also* working memory
- odds ratio 417
- olanzapine 465
- onset of disease 274, 457
 - possible origins of delayed onset 279–281
 - sex differences 331
- oogenesis 182
- Otx2* gene 9
- outcome measures 441–442, 444–445
- p75^{NTR} receptor 15
- pandepvelopmental retardation 418
- parent-of-origin effects 178–179
- parents
 - communication deviance 227
 - early parental loss 228
 - mother–child relationship 226
 - reliability of parental diagnoses 440
- parietal lobe, in velo–cardio–facial syndrome 129, 130
- parvalbumin 313, 314, 315
 - chandelier neurons 320
 - wide-arbor neurons 320–321
- Pax6 10
- pediatric neuroimaging 49, 57–59, 63
 - abnormal populations
 - ADHD 57
 - dyslexia 57–58
 - schizophrenia 58–59

484 Index

- pediatric neuroimaging (*cont.*)
 - challenges to pediatric neuroimaging 59–61
 - differences in performance 60–61
 - head movement 59–60
 - respiratory and heart rate cycles 60
 - stress 59
 - structural differences between child and adult brain 60
 - future directions 61–63
 - see also specific types of imaging*
- perigiantocellularis region 276
- periventricular hemorrhage (PVH) 94
- periventricular hemorrhagic infarction (PHI) 93
- periventricular leukomalacia (PVL) 93
- PET *see* positron emission tomography
- phencyclidine (PCP) psychosis 253
- phenotype 138, 147–148
 - behavioral
 - childhood developmental delays 123–124
 - childhood velo-cardio-facial syndrome 124–125
 - see also* endophenotypes
- phosphodiesterases (PDEs) 62, 380
- phospholipid breakdown 380
- phosphomonoesters (PMEs) 62, 380
- PIK4CA gene 127
- plasticity 89–90
 - following brain injury 91–92, 99–101
 - at the connectivity level 100–101
 - at the neural network level 99–100
 - at the neuronal level 99
 - Kennard principle 91
 - remapping of functions 100
 - rerouting 100–101
 - following preterm birth 92, 96–97, 99–101
 - limits of 101
 - see also* brain development
- polysialic acid (PSA) 12–13
- positive symptoms 375
 - attenuated prodromal symptoms 457
- positron emission tomography (PET),
 - developmental studies 47
- POU domain family 9–10
- Prader–Willi syndrome 184
- predictors of schizophrenia 415–417, 428–429, 441–444, 447
 - behavioral predictors 425–426, 428, 437–438
 - archival–observational studies 428
 - high-risk studies 427
 - population-based studies 425–427
 - electrophysiological measures 443
 - minor physical anomalies 443
 - negative predictive value 417
 - neuroimaging measures 443–444
 - neurointegrative predictors 416, 417–419, 443
 - archival–observational studies 419
 - high-risk studies 418
 - population-based studies 417–418
 - neuropsychological predictors 419–425
 - cognitive deficits 442–443, 458
 - high-risk studies 423–424, 425
 - population-based studies 419–422, 423
 - positive predictive value 417
 - prodromal symptoms 438–439
 - sensitivity 417, 421–423
 - specificity 417, 421–423
 - see also* high-risk population studies; premorbid phase; risk factors
- prefrontal cortex
 - dorsolateral (DLPFC) 310, 314, 319
 - structural abnormalities in schizophrenia 321–323
 - see also* MDN–DLPFC circuitry
 - in ADHD 57, 393–395
 - in bipolar disorder 401
 - in major depressive disorder 401
 - in obsessive–compulsive disorder 396
 - in schizophrenia 55, 274–275
 - metabolic changes 216–217, 380
 - possible origins of delayed onset 280–281
 - maturation 46
 - microarray studies 215–220
 - role in voluntary response suppression 52–53
 - role in working memory 49–51, 310–311
 - stress and emotional reactivity relationships 275–277
- premorbid phase 415, 456, 457–458, 460
 - cognitive impairments 455–457
 - progressive impairment 376
 - etiological factors 462
 - premorbid adjustment 363–364
 - premorbid personality and drug abuse 255–257
 - primary prevention strategies 463–464
 - see also* high-risk population studies; predictors of schizophrenia
- premorbid structural abnormalities 347, 364–365
 - high-risk population studies 350–353
 - Edinburgh High Risk Study 350–351
 - Melbourne High Risk Study 351–353
 - premorbid adjustment and 363–364

485 Index

- structural imaging and risk factors 353
 - family history 353–360
 - see also* premorbid phase
- prenatal infections 193–194, 362
 - influenza 192–194
- prenatal risk factors *see* risk factors
- preterm birth 92, 93
 - consequences of persisting brain abnormality 96–97
 - behavior 97
 - neurology 96
 - neuropsychology 96–97
 - limits of brain plasticity 101
- perinatal brain injuries 93–94
 - link between brain structure and function 97–98
 - prevalence 94
 - sequelae in adolescent brains 94–96
- possible plasticity mechanisms 99–101
 - at the connectivity level 100–101
 - at the neural network level 99–100
 - at the neuronal level 99
 - remapping of functions 100
 - rerouting 100–101
- University College Hospital London study 92–93
 - follow-up 93
- prevention *see* intervention strategies
- prion protein (PRNP) gene 149
- probes *see* DNA microarray studies
- prodromal phase 432, 438–439, 456, 457
 - clinical high-risk strategies 438–439
 - intervention strategies 464–467
 - low-dose atypical antipsychotic drugs 465
 - naturalistic treatment studies 465–466
 - non-antipsychotic medications 466
 - psychotherapeutic treatments 466–467
 - progressive cognitive impairment 375–376
 - subthreshold symptoms 445, 457
- proline dehydrogenase (PDH) 127
- proneural genes 6–7
- prosencephalon development 5–6
- prostaglandins 162
- proteolipid protein 1 (PLP1) 219
- pruning *see* synaptic pruning
- psychosis
 - drug-induced 250–254
 - early functional decline 457
 - neurotoxicity of untreated psychosis 380–381, 459
 - onset 457
 - see also* schizophrenia
- psychotherapeutic treatments 466–467
- PSYN group genes 215–216, 218, 219
- puberty 70
- racial discrimination 235–236, 239
- Reelin 13–14
 - RELN gene 14
 - polymorphisms 14
 - role in schizophrenia 14
- regulator of G-protein signaling 4 (RGS4) 217–218
- remapping plasticity 100
- rerouting plasticity 100–101
- response suppression 51–55
 - developmental studies 51–55, 77
 - prefrontal cortex role 52–53
- retrospective studies 434
- Rett syndrome 184
- rhesus incompatibility as risk factor 195
- rhombencephalon development 5–6
- risk factors 191, 353
 - family history 353–360
 - CT studies 354–355
 - structural MRI studies 355–356
- neonatal risk factors 200
 - neonatal and early childhood infections 194
- obstetric complications 143, 175, 197–199, 200–202, 403
 - imaging abnormalities and 360–363
- prenatal risk factors 191–197, 201, 274
 - malnutrition 194–195
 - minor physical anomalies 195–196
 - prenatal infection 192–194, 362
 - rhesus incompatibility 195
 - stress exposure 196–197
 - time and place of birth 191–192, 362
- schizotypal personality disorder 358
- see also* drug abuse; high-risk population
 - studies; predictors of schizophrenia; social factors; urban effect
- risperidone 465
- rubella, prenatal, as risk factor 193
- schizophrenia 79–82
 - brain structure 141–142, 174, 347–348, 350
 - molecular genetics 148–149
 - prefrontal cortex 55
 - state versus trait 142–143

486 Index

- schizophrenia (*cont.*)
 - chemical changes
 - BDNF 16
 - NCAM 13
 - SNAP-25 20
 - common neuropathology 112–113, 390–392, 402–403, 404–405
 - early course of disease 456, 457
 - see also* neurodegenerative models;
 - premorbid phase; prodromal phase
 - onset of disease 274, 457
 - possible origins of delayed onset 279–281
 - sex differences 331
 - outcome variability 157–158
 - postmortem findings 295–298, 376–378
 - dopamine system 297–298
 - GABA system 296–297
 - see also* genetics of schizophrenia;
 - neurodegenerative models;
 - neurodevelopmental model
 - schizophrenia spectrum of psychopathology 444–445
 - schizotypal personality disorder 358
 - schizotypy 255, 445
 - drug abuse association 255–256
 - school change in adolescence 232
 - season of birth, as risk factor 191–192, 362
 - segmentation 8–10
 - self-medication 249
 - sensitive periods *see* critical periods
 - separation anxiety disorder 125
 - serotonergic system
 - development 333–334
 - estrogen effect 336
 - serotonin 333
 - seven-pass transmembrane cadherins 11
 - sex chromosomes 330
 - see also* X chromosome
 - sex differences
 - brain development 332–333
 - aging 332–333
 - estrogen role 334–335
 - myelination 332
 - brain structure 40–41, 331–332
 - amygdala 41
 - basal ganglia 40–41
 - cerebral volume 40
 - hippocampus 41
 - schizophrenia 331
 - clinical features 331
 - epidemiology 331
 - sex steroids 330
 - see also* estrogen
 - smooth pursuit eye movements (SPEM) 438, 443
 - SNAP-25 18, 19–20
 - changes in schizophrenia 20
 - SNARE proteins 18–19
 - see also* SNAP-25; syntaxins
 - social cognition 339
 - social drift 230–231
 - social factors 224, 225, 239–240
 - animal research on brain development 224–226
 - family factors 226–229
 - childhood abuse 228–229, 239
 - communal upbringing 227–228
 - dysfunctional family environment 227
 - early parental loss 228
 - expressed emotion 228
 - family communication deviance 227
 - mother–child relationship 226
 - unwantedness 226–227
 - interaction with other factors 237–238
 - cognitive processing 238
 - gene–environment interaction 237–238
 - life events 236–237
 - social causation versus social selection 238–239
 - social isolation 232–236
 - African-Caribbeans in the UK 234–235
 - at time of onset 233
 - discrimination 235–236, 239
 - during childhood 232
 - in young adult life 232–233
 - methodological issues 234
 - migration and ethnic minority status 233–234
 - moving schools in adolescence 232
 - second generation 235
 - unemployment 236
 - socioeconomic factors 237
 - impact on outcome 157–158
 - see also* urban effect
 - social maladjustment as predictor 425, 427
 - see also* behavior
 - social residue theory 231
 - sodium valproate, teratogenic effects 184–185
 - Sonic hedgehog (Shh)* gene 7
 - speech difficulties as predictor 421
 - see also* language development
 - spermatogenesis 182

487 Index

- strategic rerouting 101
- stress 277, 281, 285
 - as risk factor 236–237
 - prenatal exposure 196–197
 - hippocampal damage 279–281
 - pediatric neuroimaging and 59
 - possible origins of delayed disease onset 279–281
 - prefrontal cortex and 275–277
 - role in neurodegeneration 382
- structural magnetic resonance imaging (sMRI) *see* magnetic resonance imaging
- substance abuse *see* drug abuse
- subthreshold symptoms 445, 457
- susceptibility genes
 - identification of 138, 217–218
 - multifactorial susceptibility model 138
 - see also* endophenotypes
- Suzuki method 90
- synapsins 20–22
 - synapsin I 21
 - synapsin II 21–22, 216
 - synapsin III 21, 22
- synaptic apoptosis 377–378
 - see also* synaptic pruning
- synaptic marker reduction 377
- synaptic pruning 39–40, 47, 130, 218, 458–459, 461
 - DLPFC 318–319
 - during adolescence 70–71, 458, 462
 - magnetic resonance spectroscopy studies 62
 - plasticity following brain injury 99
- synaptic transmission 18–23
 - impaired synaptic function 218
- synaptobrevins 18
- syntaxins 18, 22
- TBX1* gene 127–128
- telencephalon 6
- temporal lobe
 - in unaffected relatives 146
 - in velo-cardio-facial syndrome 129–130
- teratogenic effects on epigenetic regulation 184–185
- testosterone role in brain development 334
- thalamocortical projections *see* MDN–DLPFC circuitry
- thalamus
 - axon development 318
 - volume changes
 - in high-risk population 350, 357
 - in obsessive-compulsive disorder 399
 - in schizophrenia 146, 321, 349
 - see also* mediodorsal nucleus
- topiramate 467
- total brain size *see* brain
- Tourette’s syndrome 40
- transcription factors 10, 176
 - see also specific factors*
- transcriptomes 210
 - assessment methods 210–212
 - experimental design in microarray studies 212–213
 - future directions 220
 - gene expression changes in schizophrenia 215–220
 - microarray data analysis and interpretation 214–215
- trinucleotide repeats 339–340
- Trk (tyrosine kinase) receptors 15–16
 - TrkA 15, 16
 - TrkB 13, 15
 - TrkC 15, 16
- tumor necrosis factor receptor II (TNF-RII) gene 149
- Turner syndrome 338–339
- twin studies 435
 - brain structure 139–141, 143, 355–356
 - cerebral volume 145
 - corpus callosum 147
 - frontal lobe 147
 - discordance in monozygotic twins 179
 - obstetric complications 360–361
- tyrosine kinase receptors *see* Trk receptors
- UFDIL* gene 127
- ultra-high-risk population study 351–353
 - see also* high-risk population studies
- undernutrition 156, 158
 - see also* nutrition
- unemployment 236
- universal intervention 463–464
- University College Hospital London preterm birth study 92–93
 - see also* preterm birth
- unwantedness 196, 226–227
- urban effect 230–232
 - city of birth 191, 230
 - city of upbringing 230
 - possible explanations 231–232
 - social drift and social residue theories 230–231

488 Index

- valproic acid, teratogenic effects 184–185
 - velo-cardio-facial syndrome (VCFS) 122
 - as neurodevelopmental model for schizophrenia 122
 - childhood behavioral phenotype 124–125
 - childhood developmental delays 123–124
 - genetics of 126–129
 - medical aspects 122–123
 - neuroimaging 129–131
 - psychiatric presentation in adulthood 125
 - schizophrenia risk and 122, 125, 128–129
 - ventricular dilatation 111
 - following obstetric complications 360–361
 - following preterm birth 94
 - sequelae in adolescent brains 95
 - genetic marker association 360
 - in high-risk population 350
 - family history 354–355
 - in schizophrenia 141, 349
 - common neuropathology 112
 - progressive change 379–380, 381
 - in unaffected relatives 144–145, 356–357
 - ventricular volume, heritability 139–140
 - vesicle-SNAREs (v-SNAREs) 18
 - vesicular ATPase 216
 - vitamin C supplementation 165
 - vitamin D hypothesis 159
 - vitamin E supplementation 163, 165
 - vitamin requirements 158–159
 - voluntary response suppression 51–55
 - developmental studies 51–55, 77
 - prefrontal cortex role 52–53
 - voxel-based morphometry (VBM) 349
 - Wernicke’s area 38
 - white matter 36–38
 - changes during adolescence 71, 332
 - changes in major depressive disorder 401
 - sequelae of preterm birth 95
 - wide-arbor neurons 320–321
 - Wnt signaling pathway 7
 - abnormalities 8
 - working memory
 - development 49–51, 73
 - in schizophrenia 80–81
 - structural correlates 76
 - DLPFC role 310–311
 - dysfunction in schizophrenia 310–311
 - see also* cognitive dysfunction
 - in high-risk group 58–59, 274–275
 - oculomotor delayed response task 58–59
 - pediatric studies 50–51
 - prefrontal cortex role 49–51
 - thalamic mediolateral nucleus role 310–311
- X chromosome 338–341
 - trinucleotide repeats 339–340
 - Xash3* gene 6
 - Yemenite Jews 235
 - Zucker Hillside Recognition and Prevention (RAP) program, New York 465–466